Physician profile
Aaron D Mclemore
NPI 1770780108
$3,177.28
in general payments reported to CMS, 2019-2025
25 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $414 · 2021: $304 · 2022: $410 · 2023: $457 · 2024: $293 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.47 |
| Education | $145.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $554.23 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $468.48 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Insmed, INC. | $388.75 | 2020-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $368.74 | 2019-2025 | |
| Melinta Therapeutics, LLC | $206.46 | 2019-2024 | Rezzayo |
| Pfizer INC. | $168.12 | 2019-2024 | |
| Amgen INC. | $153.41 | 2019-2023 | Evenity |
| Jazz Pharmaceuticals INC. | $124.88 | 2020-2024 | |
| Axsome Therapeutics, INC. | $123.44 | 2025 | Auvelity |
| Novo Nordisk INC | $74.29 | 2021-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $61.24 | 2021-2022 | |
| Theratechnologies INC. | $60.29 | 2020-2021 | |
| Janssen Biotech, INC. | $55.23 | 2019-2020 | |
| Abbott Laboratories | $53.52 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $52.45 | 2023 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.54 | 2023-2024 | Cologuard Collection Kit |
| Emd Serono, INC. | $39.74 | 2025 | |
| Paratek Pharmaceuticals, INC. | $33.52 | 2019-2025 | Nuzyra |
| Allergan, INC. | $26.65 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $25.99 | 2021-2024 | Xacduro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $22.50 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $16.66 | 2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $16.05 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.55 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mclemore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.